Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 499

1.

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.

Karron RA, Belshe RB, Wright PF, Thumar B, Burns B, Newman F, Cannon JC, Thompson J, Tsai T, Paschalis M, Wu SL, Mitcho Y, Hackell J, Murphy BR, Tatem JM.

Pediatr Infect Dis J. 2003 May;22(5):394-405.

PMID:
12792378
2.

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children.

Karron RA, Wright PF, Newman FK, Makhene M, Thompson J, Samorodin R, Wilson MH, Anderson EL, Clements ML, Murphy BR, et al.

J Infect Dis. 1995 Dec;172(6):1445-50.

PMID:
7594701
3.

Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants.

Karron RA, Makhene M, Gay K, Wilson MH, Clements ML, Murphy BR.

Pediatr Infect Dis J. 1996 Aug;15(8):650-4.

PMID:
8858666
4.

Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.

Belshe RB, Newman FK, Tsai TF, Karron RA, Reisinger K, Roberton D, Marshall H, Schwartz R, King J, Henderson FW, Rodriguez W, Severs JM, Wright PF, Keyserling H, Weinberg GA, Bromberg K, Loh R, Sly P, McIntyre P, Ziegler JB, Hackell J, Deatly A, Georgiu A, Paschalis M, Wu SL, Tatem JM, Murphy B, Anderson E.

J Infect Dis. 2004 Feb 1;189(3):462-70.

5.

Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.

Englund JA, Karron RA, Cunningham CK, Larussa P, Melvin A, Yogev R, Handelsman E, Siberry GK, Thumar B, Schappell E, Bull CV, Chu HY, Schaap-Nutt A, Buchholz U, Collins PL, Schmidt AC; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1096 Study Group..

Vaccine. 2013 Nov 19;31(48):5706-12. doi: 10.1016/j.vaccine.2013.09.046.

7.

A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children.

Karron RA, Wright PF, Hall SL, Makhene M, Thompson J, Burns BA, Tollefson S, Steinhoff MC, Wilson MH, Harris DO, et al.

J Infect Dis. 1995 May;171(5):1107-14.

PMID:
7751684
8.

Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children.

Karron RA, Wright PF, Crowe JE Jr, Clements-Mann ML, Thompson J, Makhene M, Casey R, Murphy BR.

J Infect Dis. 1997 Dec;176(6):1428-36.

9.

Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants.

Karron RA, Wright PF, Belshe RB, Thumar B, Casey R, Newman F, Polack FP, Randolph VB, Deatly A, Hackell J, Gruber W, Murphy BR, Collins PL.

J Infect Dis. 2005 Apr 1;191(7):1093-104.

10.

Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.

Belshe RB, Newman FK, Anderson EL, Wright PF, Karron RA, Tollefson S, Henderson FW, Meissner HC, Madhi S, Roberton D, Marshall H, Loh R, Sly P, Murphy B, Tatem JM, Randolph V, Hackell J, Gruber W, Tsai TF.

J Infect Dis. 2004 Dec 15;190(12):2096-103.

11.

Current status of vaccines for parainfluenza virus infections.

Sato M, Wright PF.

Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S123-5. doi: 10.1097/INF.0b013e318168b76f. Review.

PMID:
18820572
12.

A cold-adapted mutant of parainfluenza virus type 3 is attenuated and protective in chimpanzees.

Hall SL, Sarris CM, Tierney EL, London WT, Murphy BR.

J Infect Dis. 1993 Apr;167(4):958-62.

PMID:
8383726
13.
14.

Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers.

Madhi SA, Cutland C, Zhu Y, Hackell JG, Newman F, Blackburn N, Murphy BR, Belshe RB, Karron RA, Deatly AM, Gruber WC, Bernstein DI, Wright PF.

Vaccine. 2006 Mar 20;24(13):2432-9.

PMID:
16406170
15.

Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children.

Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F; MI-CP149 Investigators..

Pediatr Infect Dis J. 2012 Feb;31(2):109-14. doi: 10.1097/INF.0b013e31823386f1.

PMID:
21926667
16.

Antibody responses to bovine parainfluenza virus type 3 (PIV3) vaccination and human PIV3 infection in young infants.

Lee MS, Greenberg DP, Yeh SH, Yogev R, Reisinger KS, Ward JI, Blatter MM, Cho I, Holmes SJ, Cordova JM, August MJ, Chen W, Mehta HB, Coelingh KL, Mendelman PM.

J Infect Dis. 2001 Oct 1;184(7):909-13.

17.
18.
19.

Safety and immunogenicity of a cold-adapted influenza A (H1N1) reassortant virus vaccine administered to infants less than six months of age.

Karron RA, Steinhoff MC, Subbarao EK, Wilson MH, Macleod K, Clements ML, Fries LF, Murphy BR.

Pediatr Infect Dis J. 1995 Jan;14(1):10-6.

PMID:
7715982
20.

Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children.

Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chambonneau L, Saluzzo JF, Bhamarapravati N.

Pediatr Infect Dis J. 2004 Feb;23(2):99-109.

PMID:
14872173
Items per page

Supplemental Content

Support Center